2. Action on Cancer Inequalities: Our Shared Roadmap
European Cancer Organisation
177 videos
Welcome! From here you can access useful information and resources from the European Cancer Organisation, its European Cancer Summit 2022, Member Societies, Patient Advocacy Groups and Community...
Read More
Welcome! From here you can access useful information and resources from the European Cancer Organisation, its European Cancer Summit 2022, Member Societies, Patient Advocacy Groups and Community 365.
European Cancer Organisation
Speakers
Professor Mark Lawler is Board Member, European Cancer Organisation and Special Network on the Impact of COVID-19 on...
Professor Mark Lawler is Board Member, European Cancer Organisation and Special Network on the Impact of COVID-19 on Cancer Co-Chair, Associate Pro-Vice-Chancellor, Professor of Digital Health, and Chair in Translational Cancer Genomics, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast (QUB). Mark is an internationally renowned scientist who has published over 200 papers including key publications in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet Oncology, Cancer Discovery, Nature Comms, Gut). His work has been recognised by numerous national/international awards including the Vander Molen Prize for Leukaemia Research, Ely Lilly Prize, St Lukes Medal for Cancer Research, Graves Medal for Medical Research and the prestigious 2018 European Health Award. Mark is Associate Director of Health Data Research Wales-Northern Ireland, one of 6 Health Data Research UK (HDR-UK) Substantive Sites, which is driving innovative precision medicine and population health approaches through the use of Big Data. He is Scientific Director for DATA-CAN, the UK Health Data Research Hub for Cancer. In the wake of the Cambridge Analytica/Facebook scandal, Mark led a pan European group in developing a roadmap to restore public trust in health data, published in Lancet Oncology. In the context of the recent COVID-19 pandemic, Mark is employing a data-driven approach to understand and mitigate the effects of COVID-19 on cancer patients and cancer systems Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the Global Alliance for Genomics and Health, an international cooperative dedicated to effective and responsible sharing of genomic/clinical data. He authored a number of key papers, including a blueprint for cancer data sharing (Nature Medicine) and a call to action for a Global Cancer Data Knowledge Network (New Engl J Med). Mark is the Queen's Lead of the £5M Medical Research Council-Cancer Research UK funded Stratified Medicine in Colorectal Cancer Consortium (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in colorectal cancer (CRC). His international reputation in CRC was instrumental in his leading a Critical Gaps in CRC Research Initiative, published in the high impact factor journal Gut; this landmark publication has attracted significant global attention (his podcast had the most “hits” of any article in the journal). Mark is a member of the Board of the European Alliance for Personalised Medicine (EAPM) and led the development of EAPM’s research strategy. He is also a member of the Scientific Advisory Board of the European Cancer Patient Coalition and of the Strategic Advisory Board of Genomics England. Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was architect of the European Cancer Patient's Bill of Rights (BoR), a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been translated into 17 European languages and adopted in 25 European countries. It was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. The BoR received The 2018 European Health Award, a prestigious award for partnerships that yield real health impact in Europe which Mark received with ECCO colleagues during the 2018 European Health Forum Gastein, the premier European health policy conference. Mark’s has a particular interested in addressing cancer challenges in Central and Eastern Europe (CEE) and has highlighted the need for data-enabled research, including economic evaluation to empower cancer control strategies in the region. He is also committed to optimal pathology and laboratory medicine provision for citizens in resource-limited settings and was senior author of a paper in The Lancet as part of The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle- Income Countries. He is leading the Lancet Oncology Groundshot Commission to provide the evidence base and road map for cancer research in Europe, with a particular focus on CEE countries, whose results will feed into the EU cancer mission.
Dr Nicolò Matteo Luca Battisti is a Consultant Medical Oncologist in the Breast Unit of The Royal Marsden NHS...
Dr Nicolò Matteo Luca Battisti is a Consultant Medical Oncologist in the Breast Unit of The Royal Marsden NHS Foundation Trust, London, UK, where he is also Clinical Lead of the Senior Adult Oncology Programme. He completed his specialist training at the University of Milan and National Cancer Institute of Milan, Italy in 2015. He obtained a research degree (MD[Res]) within the Breast Cancer Research Division of the Institute of Cancer Research of London, UK in 2022. Dr Battisti completed the European Society for Medical Oncology Leaders Generation Programme in 2022. He spent the last year of his specialist training working with Dr Martine Extermann at the Senior Adult Oncology Program of the Moffitt Cancer Center of Tampa, Florida, USA. In 2016, Dr Battisti joined the Breast Unit of The Royal Marsden NHS Foundation Trust. Dr Battisti’s main clinical and research interests are breast oncology and geriatric oncology. He authored several publications and book chapters in the fields of geriatric and breast oncology. Dr Battisti is President of the International Society of Geriatric Oncology (SIOG). He also serves as Co-Chair of the European Cancer Organisation Inequalities Focused Topic Network. He is a member of the Elderly Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) and member of the Cancer and Aging Research Group (CARG) Advocacy Committee and Clinical Implementation Core. He is a member of the Clinical Steering Group of the National Audit of Breast Cancer in Older Patients (NABCOP) in the UK. Dr Battisti was presented the Arti Hurria Award at the 2019 San Antonio Breast Cancer Symposium for his research on the use of chemotherapy in older patients with early breast cancer enrolled within the Bridging The Age Gap study and in 2021 he was presented the Dario Cova Award from the Italian Group of Geriatric Oncology for his contribution to the field of geriatric oncology.
Richard Sullivan is Editor-in-chief, Journal of Cancer Policy Director, Institute of Cancer Policy, King's College...
Richard Sullivan is Editor-in-chief, Journal of Cancer Policy Director, Institute of Cancer Policy, King's College London & Professor of Cancer and Global Health at King’s College London, and Director of the King’s Institute of Cancer Policy and co-Director of the Conflict and Health Research Group (kcl.ac.uk/research/conflict-health-research-group). His research interests extend from global cancer to conflict & health. Richard has worked on a number of Lancet and Lancet Oncology commissions, currently the Lancet Commission on Global Diagnostics (diagnosticscommission.org) and the Lancet Oncology European Cancer Research Commission. Richard’s research teams have major programs in capacity building in conflict and health, and humanitarian medicine, particularly in the Middle East and North Africa (r4hc-mena.org), as well as programmes in women’s health and cancer, digital innovation (virtual-reality enhanced surgery) and a wide range of global health security projects including on the COVID-19 pandemic and strengthening health systems in NW and NE Syria. His global cancer research programs cover cancer systems strengthening, affordability, value particularly and political economy, global radiotherapy, social welfare and cancer care in conflict. Professor Sullivan qualified in medicine and trained in surgery (urology) gaining his PhD in Biochemistry from University College London. Richard was Clinical Director of Cancer Research UK between 1999 and 2008. He has also worked for many years on biosecurity and counterproliferation issues, including Ebola outbreaks in West Africa and DR Congo. Richard is an NCD advisor to the WHO, a member of the National Cancer Grid of India and advisor (civil-military) to Save the Children.
Start a conversation